Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single- chain Fv fusion immunotoxin specifically targeting the CD3ε moiety of the T- cell receptor

Blood

Volumn 88, Issue 6, 1996, Pages 2342-2353

  Vallera, Daniel A ^a   Panoskaltsis Mortari, Angela ^b   Jost, Carolina ^b   Ramakrishnan, S ^b   Eide, Cindy R ^b   Kreitman, Robert J ^b   Nicholls, Peter J ^b   Pennell, Christopher ^b   Blazar, Bruce R ^b  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY CD3; RECEPTOR SUBUNIT; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; ESCHERICHIA COLI; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0029840435     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.6.2342.bloodjournal8862342     Document Type: Article

References (56)

1. Korngold R, Sprent J: T cell subsets and graft-versus-host disease. Transplantation 44:335, 1987
2. Grebe SC, Strelein JW: Graft-versus-host-disease. Adv Immunol 22:119, 1976
3. Vallera DA: Targeting T cells for GVHD therapy. Semin Cancer Biol 7:57, 1996
4. Vallera DA, Carroll SF, Snover D, Carlson GJ, Blazar BR: Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Blood 77:182, 1991
5. Cavazzana-Calvo M, Stephan JL, Samacki S, Chevret S, Fromont C, de Coene C, Le Deist F. Guy-Grand D, Fischer A: Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 83:288, 1994
6. 2-RTA (ricin toxin A chain) immunotoxin. Blood 86:4367, 1995
7. Byers VS, Henslee J, Kernan N, Blazar BR, Gingrich R, Phillips GL, LeMaistre CF, Gilliland G, Antin JH, Vogelsang G, Martin P, Tutschka PJ, Trown P, Ackerman SK, O'Reilly RJ, Scannon PJ: Use of anti-pan T lymphocyte ricin A chain immunotoxin as targeted immunotherapy in steroid resistant acute graft-versus-host disease. Blood 75:1426, 1990
8. Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B: Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplant 12:531, 1993
9. Krance R, Heslop HE, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, Horowitz MM, Brenner MK: Antipan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant 11:33, 1993
10. Van Ness BG, Howard JB, Bodley JW: ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. J Biol Chem 255:10710, 1980
11. Endo Y, Mitsui K, Motizuki M, Tsurugui I: The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem 262:5908, 1987
12. Collier JR: Structure-activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotosin A, in Frankel AE (ed): Immunotoxins. Norwell, MA, Kluwer Academic, 1988, p 25
13. Colombatti M, Greenfield L, Youle RJ: Cloned fragment of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry. J Biol Chem 261:3030, 1986
14. Royston I, Majda JA, Baird SM, Meserve BL, Griffiths JC: Human T cell antigens defined by monoclonal antibodies: The 65000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol 125:725, 1980
15. Press OW, Vitetta ES, Farr AG, Hansen JA, Martin PJ: Evaluation of ricin A-chain immunotoxins directed against human T cells. Cellular Immunol 102:10, 1986
16. Preijers FWMB, De Witte T, Rijke-Schilder GPM, Tax WJM, Wessels JMC, Haanen C, Capel PJA: Human T lymphocyte differentiation antigens as target for immunotoxins or complement-mediated cytotoxicity. Scand J Immunol 28:185, 1988
17. Bierer BE, Burakoff SJ, Smith BR: A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation. Blood 73:1359, 1989
18. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with the whole monoclonal antibody. Transplantation 49:1117, 1990
19. Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA: In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T-cell depleted marrow for the promotion of engraftment. J Immunol 147:1492, 1991
20. Vallera DA: Immunotoxins: Will their clinical promise be fulfilled? Blood 83:309, 1994
21. Bosma GC, Custer RP, Bosma MJ: A severe combined immunodeficiency in the mouse. Nature 301:527, 1983
22. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR: Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension. Gene 77:61, 1989
23. Chan C-H, Blazar BR, Eide CR, Kreitman RJ, Vallera DA: A murine cytokine fusion toxin specifically targeting the murine GM-CSF receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells. Blood 87:2732, 1995
24. Jost CR, Kurucz I, Jacobus CM, Titus JA, George AJT, Segal DM: Mammalian expression and secretion of functional single-chain Fv molecules. Exp Immunol 269:26267, 1994
25. 390-mIL-3, with bone marrow progenitor cells. Blood 88:1445, 1996
26. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248, 1976
27. Leo O, Foo M, Sachs DH, Samuelson LE, Bluestone JA: Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1087:1374, 1984
28. Houlden BA, Matis LA, Cron RW, Widacki SM, Brown Gd, Pampeno C, Merulo D, Bluestone JA: A TCR γδ cell recognizing a novel TL-encoded gene product. Cold Spring Harb Symp Quant Biol 54:45, 1989
29. Vallera DA, Youle RJ, Neville DM Jr, Kersey JH: Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal GVHD by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. J Exp Med 155:949, 1982
30. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone JA, Vallera DA: Lethal murine graft-versus-host-disease induced by donor expressing T cells with specificity for host nonclassical MHC class Ib antigens. Blood 87:827, 1996
31. Dialynas DM, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW: Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK 1.5. J Immuno 131:2445, 1983
32. Ledbetter JA, Rouse R, Spedding-Micklem H, Herzenberg L: T cell subsets defined by expression of Lyt-1, 2, and 3 and Thy-1 antigens. J Exp Med 152:280, 1980
33. Kubo RT, Born W, Kappler JW, Marrack P, Pigeon M: Characterization of a monoclonal antibody which detects all murine α/ β T cell receptors. J Immunol 142:2736, 1989
34. Jansen B, Vallera DA, Jaszcz WB, Nguyen D, Kersey J: Successful treatment of human acute T-cell leukemia in SCID mice using anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res 52:1314, 1992
35. Ey PL, Prouse SJ, Jenkin CR: Isolation of pure IgG1, IgG2a, and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 15:429, 1978
36. Unkless JC: Characterization of monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580, 1979
37. Hsu S-M, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577, 1981
38. Mantel N: Evaluation of survival data in two new rank order statistics arising in its consideration. Cancer Chemother 50:163, 1966
39. Greenfield L, Johnson VG, Youle RJ: Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238:536, 1987
40. Thompson J, Huaizhong H, Scharff J, Neville DM Jr: An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 270:28037, 1995
41. Saito T, Kreitman RJ, Hanada S, Makino T, Utsunomiya A, Sumizawa T, Arima T, Chang CN, Hudson D, Pastan I: Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble inlerleukin-2 receptor. Cancer Res 54:1059, 1995
42. Benhar I, Reiter Y, Pai LH, Pastan I: Administration of disulfide-stabilized Fv-immunotoxins B1 (dsFv)-PE38 and B3 (dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int J Cancer 62:351, 1995
43. Webber KO, Reiter Y, Brinkmann U, Kreitman R, Pastan I: Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: Comparison with its single-chain analog. Mol Immunol 32:249, 1995
44. Kreitman RJ, Pastan I: Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307:29, 1995
45. Volkman DJ, Ahmad A, Fauci AS, Neville DM Jr: Selective abrogation of antigen-specific human B cell responses by antigenricin conjugates. J Exp Med 156:634, 1982
46. McCarthy PL, Abhyankar S, Neben S: Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915, 1991
47. Vallera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR: IL-1 or TNF-α antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 60:1371, 1995
48. Uckun FM, Stong RC, Youle RJ, Vallera DA: Combined ex vivo treatment with immunotoxins and mafosfamid: A novel immunochemotherapeutic approach for eliminaiton of neoplastic T-cells from autologous marrow grafts. J Immunol 134:3504, 1985
49. Truitt RL, Shih CC-Y, LeFever AV, Tempelis LD, Andreani M, Bortin MM: Characterization of alloimmunization induced T lymphocytes-reactive against AKR leukemia in vitro and correlation with graft-versus-leukemia activity in vivo. J Immunol 131:2050, 1983
50. Vallera DA, Blazar BR: T cell depletion for graft-versus-host-disease prophylaxis: A perspective on engraftment in mice and humans. Transplantation 47:751, 1989
51. Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibillity complex (MHC) barrier in mice. Blood 83:3815, 1994
52. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW, Vitetta ES: Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: Implications for vascular leak syndrome. Exp Cell Res 206:227, 1993
53. Platanias LC, Ratain MJ, O'Brien S, Larson RA, Vardiman JW, Shaw JP, Williams SF, Baron JM, Parker K, Woodworth TG: Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma 14:257, 1994
54. Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG, Schnipper LE: Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73:1276, 1994
55. Kuzel TM, Rosen ST, Gordon LI, Winter J, Samuelson E, Kaul K, Roenigk HH, Nylen P, Woodworth T: Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: Efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma 11:369, 1993
56. Batra JK, Kasturi S, Gallo MG, Voorman RL, Maio SM, Chaudhary VK, Pastan I: Insertion of constant region domains of human IgG1 into CD4-PE40 increases its plasma half-life. Mol Immunol 30:379, 1993